These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 17868065)

  • 21. Mycophenolate mofetil versus azathioprine in kidney transplant recipients on steroid-free, low-dose cyclosporine immunosuppression (ATHENA): A pragmatic randomized trial.
    Ruggenenti P; Cravedi P; Gotti E; Plati A; Marasà M; Sandrini S; Bossini N; Citterio F; Minetti E; Montanaro D; Sabadini E; Tardanico R; Martinetti D; Gaspari F; Villa A; Perna A; Peraro F; Remuzzi G
    PLoS Med; 2021 Jun; 18(6):e1003668. PubMed ID: 34166370
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
    Gruessner RW
    Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of antibody induction on transplant outcomes in human leukocyte antigen zero-mismatch deceased donor kidney recipients.
    Kuo HT; Huang E; Emami S; Pham PT; Wilkinson AH; Danovitch GM; Bunnapradist S
    Transplantation; 2012 Mar; 93(5):493-502. PubMed ID: 22306574
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Single-center experience with mycophenolate mofetil in pediatric renal transplant recipients.
    Virji M; Carter JE; Lirenman DS
    Pediatr Transplant; 2001 Aug; 5(4):293-6. PubMed ID: 11472609
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mycophenolate mofetil suspension in pediatric renal transplantation: three-year data from the tricontinental trial.
    Höcker B; Weber LT; Bunchman T; Rashford M; Tönshoff B;
    Pediatr Transplant; 2005 Aug; 9(4):504-11. PubMed ID: 16048604
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reasons for dose reduction of mycophenolate mofetil during the first year after renal transplantation and its impact on graft outcome.
    Vanhove T; Kuypers D; Claes KJ; Evenepoel P; Meijers B; Naesens M; Vanrenterghem Y; Cornelis T; Bammens B
    Transpl Int; 2013 Aug; 26(8):813-21. PubMed ID: 23746202
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tolerability of mycophenolate sodium in renal transplant recipients.
    Hiramoto LL; Tedesco-Silva H; Medina-Pestana JO; Felipe CR
    Int J Clin Pharm; 2018 Dec; 40(6):1548-1558. PubMed ID: 30302621
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients.
    Sampaio MS; Cho YW; Shah T; Bunnapradist S; Hutchinson IV
    Transplantation; 2012 Jan; 93(1):73-81. PubMed ID: 22129761
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of mycophenolate mofetil on long-term outcomes in African american renal transplant recipients.
    Meier-Kriesche HU; Ojo AO; Leichtman AB; Punch JD; Hanson JA; Cibrik DM; Kaplan B
    J Am Soc Nephrol; 2000 Dec; 11(12):2366-2370. PubMed ID: 11095660
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dose optimization of mycophenolate mofetil when administered with a low dose of tacrolimus in cadaveric renal transplant recipients.
    Squifflet JP; Bäckman L; Claesson K; Dietl KH; Ekberg H; Forsythe JL; Kunzendorf U; Heemann U; Land W; Morales JM; Mühlbacher F; Talbot D; Taube D; Tyden G; van Hooff J; Schleibner S; Vanrenterghem Y;
    Transplantation; 2001 Jul; 72(1):63-9. PubMed ID: 11468536
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Superior efficacy of enteric-coated mycophenolate vs mycophenolate mofetil in de novo transplant recipients: pooled analysis.
    Salvadori M; Bertoni E; Budde K; Holzer H; Civati G; Lien B; Arns W
    Transplant Proc; 2010 May; 42(4):1325-8. PubMed ID: 20534293
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Induction Therapy, Rejection, and Graft Outcomes in Pediatric and Adolescent Kidney Transplant Recipients.
    Mincham CM; Wong G; Teixeira-Pinto A; Kennedy S; Alexander S; Larkins N; Lim WH
    Transplantation; 2017 Sep; 101(9):2146-2151. PubMed ID: 28832451
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of tolerability and ability to increase immunosuppression in renal transplant patients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium.
    Bilodeau JF; Montambault P; Wolff JL; Lemire J; Masse M
    Transplant Proc; 2009 Nov; 41(9):3683-9. PubMed ID: 19917367
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Steroid withdrawal in renal transplant recipients.
    Oppenheimer F
    Transplant Proc; 2000 Feb; 32(1A Suppl):14S-15S. PubMed ID: 10686314
    [No Abstract]   [Full Text] [Related]  

  • 35. Mycophenolate mofetil as maintenance immunosuppression in pediatric renal transplantation.
    Ettenger R; Cohen A; Nast C; Moulton L; Marik J; Gales B
    Transplant Proc; 1997; 29(1-2):340-1. PubMed ID: 9123030
    [No Abstract]   [Full Text] [Related]  

  • 36. Effect on kidney graft survival of reducing or discontinuing maintenance immunosuppression after the first year posttransplant.
    Opelz G; Döhler B
    Transplantation; 2008 Aug; 86(3):371-6. PubMed ID: 18698238
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Significant racial differences in the key factors associated with early graft loss in kidney transplant recipients.
    Taber DJ; Douglass K; Srinivas T; McGillicuddy JW; Bratton CF; Chavin KD; Baliga PK; Egede LE
    Am J Nephrol; 2014; 40(1):19-28. PubMed ID: 24969370
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The 37-year kidney transplantation experience at Siriraj Hospital.
    Premasathian N; Vongwiwatana A; Taweemonkongsap T; Amornvesukit T; Limsrichamrern S; Jitpraphai S; Kositamongkol P; Mahawithitwong P; Sritippayawan S; Chanchairujira T; Nualyong C; Vareesangthip K; Vasuvattakul S; Sirivatanauksorn Y
    Clin Transpl; 2010; ():141-8. PubMed ID: 21696037
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mycophenolate mofetil with lower cyclosporine dose in high-risk renal transplant recipients.
    Esmeraldo RM; Donadi MO; Oliveira ML; Ponte CN; Pinheiro PM
    Transplant Proc; 1999 Nov; 31(7):3007-8. PubMed ID: 10578367
    [No Abstract]   [Full Text] [Related]  

  • 40. Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study.
    Lorber MI; Mulgaonkar S; Butt KM; Elkhammas E; Mendez R; Rajagopalan PR; Kahan B; Sollinger H; Li Y; Cretin N; Tedesco H;
    Transplantation; 2005 Jul; 80(2):244-52. PubMed ID: 16041270
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.